What are the pathogenesis, etiology, classification, risk factors, complications, diagnosis, and management of chronic osteomyelitis?

Chronic Osteomyelitis: Complete Orthopedic Overview

Definition and Pathogenesis

Chronic osteomyelitis is a persistent bone infection characterized by bone necrosis, biofilm formation, and altered vascularization that fundamentally changes treatment requirements compared to acute infection. 1

Pathophysiologic Mechanisms

The progression from acute to chronic osteomyelitis involves:

• Biofilm formation: Bacteria encased in extracellular matrix become profoundly resistant to antibiotics (up to 1000-fold reduced susceptibility) and immune clearance 1
• Vascular compromise: Infection leads to thrombosis of nutrient vessels, creating avascular bone segments
• Sequestrum formation: Necrotic bone fragments become separated from viable bone, serving as bacterial reservoirs
• Involucrum development: New bone forms around the infected area as a physiologic response
• Cloaca formation: Drainage tracts develop through bone cortex to skin surface 2

The biofilm matures over time, with declining success rates for implant retention: 90% success if treated within 3 weeks, 70% at 6 weeks, and 51-67% after 10 weeks post-fracture fixation 3. This biological timeline dictates surgical strategy more than antibiotic duration.

Etiology

Microbial Pathogens

Staphylococcus aureus is isolated in approximately 50% of chronic osteomyelitis cases 4, making it the primary empiric target. Other common pathogens include:

• Coagulase-negative staphylococci (~25%)
• Aerobic streptococci (~30%)
• Enterobacteriaceae (~40%)
• Polymicrobial infections are common, particularly in diabetic foot osteomyelitis 4

Routes of Infection

Three mechanisms lead to chronic osteomyelitis 5:

1. Hematogenous dissemination: Predominantly in children; adults with bacteremia from IV catheters, distant infection foci, or IV drug abuse
2. Direct inoculation: Penetrating trauma, surgical procedures (internal fixation, skeletal traction), diagnostic procedures
3. Contiguous spread: From adjacent soft tissue infection, particularly with vascular insufficiency; dental/sinus infections spreading to facial bones 5

Classification Systems

Cierny-Mader Classification (Primary System)

This classification integrates anatomical extent with host physiology, directly guiding treatment strategy 1:

Anatomic Types:

• Type I: Medullary osteomyelitis (confined to intramedullary canal)
• Type II: Superficial osteomyelitis (exposed infected bone surface)
• Type III: Localized osteomyelitis (full-thickness cortical involvement, stable bone)
• Type IV: Diffuse osteomyelitis (circumferential involvement, unstable bone)

Host Categories:

• A: Normal host (normal immune system and vascularity)
• B: Compromised host (Bs: systemic compromise; Bl: local compromise; Bls: both)
• C: Treatment worse than disease (prohibitive surgical risk)

Lew and Waldvogel Classification

Alternative system based on:

• Duration: Acute vs. chronic
• Mechanism: Hematogenous vs. contiguous focus (with/without vascular insufficiency)
• Anatomic site involved 2

Risk Factors

Patient-Specific Factors

Major risk factors increasing susceptibility 5:

• Vascular insufficiency: Diabetes mellitus, peripheral arterial disease
• Immunocompromise: HIV/AIDS, chronic granulomatous disease, immunosuppressive therapy
• Hematologic disorders: Sickle cell anemia (unusual susceptibility to skeletal infections)
• Metabolic conditions: Poorly controlled diabetes, malnutrition, chronic renal failure
• Substance abuse: IV drug use (hematogenous seeding)

Iatrogenic and Trauma-Related Factors

• Orthopedic hardware: Internal fixation devices, joint prostheses
• Prior surgery: Inadequate debridement of acute osteomyelitis 5
• Open fractures: Direct inoculation risk
• Penetrating injuries: Puncture wounds, animal bites
• Chronic wounds: Pressure ulcers, diabetic foot ulcers (50-60% of hospitalized diabetic foot infections have underlying osteomyelitis) 4

Diagnosis

Clinical Evaluation

Start with targeted clinical assessment focusing on high-yield findings 4:

• Probe-to-bone test: If sterile metal probe strikes bone through wound (hard, gritty feel):

  • Positive likelihood ratio: 7.2 when prevalence >60%
  • Negative likelihood ratio: 0.48 when prevalence ≤20%
  • This single test substantially changes diagnostic probability

• Ulcer characteristics: Area >2 cm² has positive LR 7.2 for underlying osteomyelitis 4

• Exposed bone: Positive LR 9.2 for osteomyelitis 4

• "Sausage toe": Erythematous, indurated digit suggests bone involvement

• Draining sinus: High suspicion for chronic infection; persistent bone infection creates continuous soft tissue infection with sinus tract formation 6

Imaging Algorithm

Follow this hierarchical approach 7:

Step 1: Plain Radiographs (Initial Study)

• Obtain in all cases except necrotic/extensive decubitus ulcers (proceed directly to surgical debridement) 7
• Chronic osteomyelitis findings: periosteal reaction, trabecular coarsening, bone fragmentation, cortical erosions, sequestra, involucrum, cloaca 6
• If negative and suspicion persists: Treat soft tissue infection 2 weeks, then repeat radiographs 2-4 weeks later 8

Step 2: MRI (Preferred Advanced Imaging)

• MRI has 100% negative predictive value—normal marrow signal reliably excludes osteomyelitis 6
• Sensitivity and specificity both high for chronic osteomyelitis 6
• Findings: decreased T1 marrow signal, increased T2/STIR signal, soft tissue/marrow edema, altered perfusion 6
• Three T1 signal patterns 2:
  • Confluent intramedullary: Most associated with osteomyelitis
  • Hazy reticular: Rarely associated with hematogenous osteomyelitis
  • Subcortical: Not associated with osteomyelitis
• Superior to CT for soft tissue extent, marrow involvement 6
• Use MRI when advanced imaging needed for diagnosis 4

Step 3: CT (Alternative/Complementary)

• Well-suited for: fracture nonunion, hardware complications, osteolysis evaluation 6
• Superior to MRI for: sequestra detection, foreign bodies, soft tissue gas 6
• Findings: cortical thickening/destruction, periosteal reaction, bone erosions, fistulae 6

Step 4: Nuclear Medicine (Limited Role)

FDG-PET (when MRI contraindicated or hardware present):

• Sensitivity 94%, specificity 87% in post-trauma chronic osteomyelitis 6
• Accuracy 91% in chronic osteomyelitis, 96% with orthopedic hardware 6
• Specificity 100% in axial skeleton 6
• Pitfall: Cannot differentiate infection from inflammation in acute post-operative/post-traumatic setting (wait 3-4 months) 6

Bone scintigraphy: Sensitivity 82%, specificity only 25%—too nonspecific 6

Leukocyte scanning: Sensitivity 61-74%, specificity 77-88%; particularly poor (21% sensitivity) in axial skeleton chronic osteomyelitis 6

Microbiologic Diagnosis

Definitive diagnosis requires both histology (inflammatory cells, necrosis) AND positive culture from aseptically obtained bone 4.

Diagnostic Sampling Algorithm 7:

1. Sinus Tract Cultures (Consider First)

• Two consecutive cultures with bone contact predict causative pathogen in 90% of monomicrobial infections 7
• Accuracy: 96% specificity, 90% predictive value compared to operative specimens 7
• Reliable for all bacteria except Staphylococcus epidermidis (hardware-associated only) 7
• More reliable when: performed twice, infection is monomicrobial
• Practical alternative when bone biopsy unavailable or high-risk 7

2. Joint Aspiration (If Septic Arthritis Present)

• Synovial fluid WBC ≥50,000 cells/mm³ suggestive (not conclusive) 7
• Culture positive in ~80% non-gonococcal septic arthritis 7
• If positive: proceed with treatment, no bone biopsy needed
• If negative: perform percutaneous bone biopsy 7

3. Percutaneous Image-Guided Bone Biopsy (Gold Standard)

• Discontinue antibiotics 2 weeks before biopsy for optimal yield 7
• Obtain 2-3 specimens: one for culture, one for histology 8
• Use CT or fluoroscopic guidance, traverse uninvolved skin 8
• Safe procedure with no published complications in foot bone biopsy 8

4. Intraoperative Cultures

• For surgical emergencies or during definitive debridement
• Multiple samples from different sites

Blood Cultures: Generally low yield in chronic osteomyelitis (more useful in axial skeleton); positive cultures indicate critical cases requiring immediate intervention 7

Laboratory Markers

Inflammatory markers (ESR, CRP) have limited diagnostic value—do not routinely order for diagnosis 9. They may help monitor treatment response but are nonspecific.

Complications

Local Complications

• Pathologic fracture: Through weakened, infected bone
• Septic arthritis: Extension into adjacent joint (26-27% complication rate in surgical series) 10
• Chronic draining sinus: Persistent soft tissue infection with cutaneous drainage 6
• Squamous cell carcinoma: Rare malignant transformation in chronic sinus tracts 6
• Soft tissue abscess: Deep space infections requiring drainage
• Bone deformity: Growth disturbance in children, angular deformities

Systemic Complications

• Sepsis: Particularly with acute exacerbations
• Amyloidosis: Rare, with prolonged untreated infection
• Antibiotic-related complications: Reported in 26.6-27.6% of surgical cases 10

Functional Complications

• Chronic pain: Persistent despite treatment
• Limb length discrepancy: Especially in pediatric cases
• Joint stiffness: From prolonged immobilization or joint involvement
• Amputation: When infection uncontrollable or limb nonsalvageable
• Recurrence: Variable rates depending on treatment adequacy

Management

Surgical Management (Primary Treatment)

Surgery is the cornerstone of chronic osteomyelitis treatment—antibiotics alone cannot eradicate biofilm-associated infection 1, 11.

Surgical Principles 1, 10:

1. Radical debridement: Remove all necrotic bone (sequestra), infected soft tissue, biofilm
2. Dead space management: Fill defects with antibiotic-loaded carriers (calcium sulfate beads used in 30.4% of cases) 10
3. Soft tissue reconstruction: Ensure viable soft tissue coverage, revascularization if needed 3
4. Bone reconstruction: Staged or simultaneous depending on infection control

Implant Management Decision Algorithm 3:

Preconditions for Implant Retention (DAIR - Debridement, Antibiotics, Implant Retention):

• Stable osteosynthetic construct
• Viable soft tissue envelope
• Ability to perform proper debridement
• Time interval: <3 weeks post-fixation (90% success), <6 weeks (70% success), >10 weeks (51-67% success) 3

If preconditions NOT met: Implant exchange (one-stage or two-stage)

Single-Stage vs. Two-Stage Surgery:

Meta-analysis of 1605 patients shows no significant difference in cure rates: 91% overall 10. Choose based on:

Single-Stage Indications:

• Adequate soft tissue coverage available
• Known pathogen, susceptible to antibiotics
• No extensive bone loss
• Good host physiology (Cierny-Mader A or B)

Two-Stage Indications:

• Extensive bone/soft tissue loss
• Unknown or resistant pathogen
• Poor soft tissue coverage
• Compromised host (Cierny-Mader Bls)
• Failed prior single-stage attempt

Antibiotic Therapy

Duration Based on Surgical Intervention 9, 3:

Osteomyelitis WITHOUT Retained Implant:

• After complete surgical resection of infected bone: 2-5 days if confident all infected bone removed 9
• After debridement (bone remaining): 3-4 weeks (based on small RCTs, including diabetic foot osteomyelitis) 9
• Traditional 6-week courses NOT supported by evidence—do not exceed 6 weeks 9

Osteomyelitis WITH Retained Implant (Including PJI):

• DAIR procedures: 12 weeks preferred over 6 weeks (unanimous expert consensus based on DATIPO trial) 9
• Prosthetic exchanges: 12 weeks for most; equipoise exists for 6 vs 12 weeks if non-S. aureus, one-stage exchange, or negative cultures before reimplantation 9
• Other infected implants: Treat until bone heals sufficiently for implant removal 9

Route of Administration:

• Oral step-down therapy after ~1 week IV is appropriate for most patients 4, 9
• Oral agents must have good bioavailability: fluoroquinolones, rifampin (always combined), clindamycin, linezolid, fusidic acid, trimethoprim-sulfamethoxazole 4

Empiric Coverage:

• Must cover S. aureus (most common pathogen) 4
• Ideally base definitive therapy on bone culture results 4

Local Antibiotic Delivery:

• High local concentrations with low systemic exposure 3
• Commercial formulations: gentamicin, tobramycin, vancomycin, clindamycin in PMMA, collagen fleeces, ceramics 3
• Thermally stable antibiotics preferred: aminoglycosides, glycopeptides, fluoroquinolones (β-lactams degrade rapidly at 37°C) 3
• Used in 30.4% of cases for dead space management 10

Suppressive Therapy:

• For patients where curative surgery unacceptable: long-term oral suppression or intermittent short courses for recrudescent symptoms 4
• Continue until implant can be removed 9

Treatment Selection Algorithm

Medical vs. Surgical Decision 4:

Favor Primary Medical Treatment When:

• Patient medically unstable for surgery
• Poor postoperative foot mechanics likely (midfoot/hindfoot infection)
• No other foot procedures needed
• Small, confined forefoot lesion
• No skilled surgeon available
• Surgery costs prohibitive
• Strong patient preference against surgery

Favor Primary Surgical Treatment When:

• Substantial bone necrosis or exposed joint
• Functionally nonsalvageable foot
• Patient already nonambulatory
• High risk for antibiotic complications
• Resistant pathogen
• Uncorrectable ischemia (precludes antibiotic delivery)
• Strong patient preference for surgery

Note: Randomized trial showed similar outcomes for primarily antibiotic vs. surgical treatment in neuropathic forefoot ulcers with osteomyelitis (no ischemia/necrotizing infection), but only one-third of screened patients were eligible 4.

Multidisciplinary Approach

Essential team members 7, 11:

• Orthopedic surgery (debridement, reconstruction)
• Infectious diseases (antibiotic selection, duration)
• Radiology (diagnosis, image-guided procedures)
• Plastic surgery (soft tissue reconstruction for complex cases)
• Vascular surgery (revascularization when needed)

Common Pitfalls

1. Ordering plain radiographs routinely when clinical suspicion low—low value, high cost 9
2. Relying on inflammatory markers for diagnosis—nonspecific, low accuracy 9
3. Obtaining bone biopsy while patient on antibiotics—reduces culture yield; stop 2 weeks prior 7
4. Treating chronic osteomyelitis with antibiotics alone—biofilm cannot be eradicated without debridement 1
5. Prolonging antibiotics beyond evidence-based durations—no benefit beyond 6 weeks for non-implant cases 9
6. Attempting DAIR >10 weeks post-fracture fixation—success rate drops to 51-67% 3
7. Confusing neuropathic arthropathy with osteomyelitis: Neuropathy involves multiple midfoot bones, has subchondral cysts, thin rim joint effusion enhancement, intra-articular bodies; osteomyelitis involves single bone subjacent to ulcer/sinus 2
8. Obtaining MRI in acute post-operative period (<3-4 months)—cannot distinguish infection from inflammation 6